Caris Life Sciences (NASDAQ:CAI) Now Covered by Analysts at Piper Sandler

Stock analysts at Piper Sandler started coverage on shares of Caris Life Sciences (NASDAQ:CAI) in a research note issued on Friday,Benzinga reports. The brokerage set a “neutral” rating and a $21.00 price target on the stock. Piper Sandler’s price objective suggests a potential upside of 9.38% from the stock’s current price.

CAI has been the topic of a number of other research reports. The Goldman Sachs Group assumed coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price target on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group dropped their target price on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research report on Friday, March 13th. BTIG Research cut their target price on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Finally, Robert W. Baird upped their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $29.00.

Caris Life Sciences Trading Down 1.6%

NASDAQ CAI opened at $19.20 on Friday. The firm has a market cap of $5.43 billion and a PE ratio of -106.67. The business has a 50-day simple moving average of $19.65. The company has a quick ratio of 7.35, a current ratio of 7.85 and a debt-to-equity ratio of 0.66. Caris Life Sciences has a twelve month low of $16.28 and a twelve month high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.01 by $0.27. The business had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. The firm’s revenue for the quarter was up 125.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.73) earnings per share.

Institutional Investors Weigh In On Caris Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zevenbergen Capital Investments LLC purchased a new stake in Caris Life Sciences during the 4th quarter valued at about $14,655,000. Hamilton Lane Advisors LLC purchased a new position in Caris Life Sciences in the 4th quarter worth approximately $1,584,000. Olistico Wealth LLC acquired a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $31,000. Michael & Susan Dell Foundation purchased a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $330,000. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Caris Life Sciences by 15.0% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 11,932 shares of the company’s stock valued at $322,000 after purchasing an additional 1,560 shares in the last quarter.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.